News

Newton Biocapital is one of the 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem

Newton Biocapital is one of the 8 VC Firms Certified for AMED Funding Project to Boost Pharma Ecosystem

On June 30, the Japan Agency for Medical Research and Development (AMED) has selected eight VC firms including Newton Biocapital as certified VCs to boost the country’s drug discovery ecosystem in Japan.

Under this initiative, AMED will provide additional funding for drug discovery start-ups that has received investments from these certified VC firms. AMED will compliment two times the amount invested by these VCs. The Japanese government has set aside a budget of 50 billion yen for this project.

The eight VC firms selected are: 1) Remiges Ventures, 2) Fast Track Initiative, 3) DCI Partners, 4) Catalys Pacific, 5) Newton Biocapital Partners, 6) Mitsubishi UFJ Capital, 7) Kyoto University Innovation Capital, and 8) UTokyo Innovation Platform.

Application deadline to AMED certification program was March 2022 with hearings with the applicants conducted in June 2022. A total of 24 companies applied for that initiative which triggered 8 certifications.

The agency will invite drug discovery start-ups that wish to apply for funding under that initiative and the selection is expected by the end of 2022.

About AMED (EN) & VC Certification Info (JP):

https://www.amed.go.jp/en/aboutus/index.html

https://www.amed.go.jp/koubo/19/02/1902C_00003.html

Pharma Japan (EN):

https://pj.jiho.jp/article/247025